MN-221-CL-007: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma.

Trial Profile

MN-221-CL-007: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2013

At a glance

  • Drugs Bedoradrine (Primary) ; Ipratropium bromide; Salbutamol
  • Indications Acute asthma; Status asthmaticus
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2012 Results will be presented at the Fourth World Congress of Emergency Medicine, according to a MediciNova media release.
    • 23 May 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has not been met.
    • 23 May 2012 Preliminary results were reported in a MediciNova media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top